公开(公告)号：US20190261666A1

公开(公告)日：2019-08-29

申请号：US16406276

申请日：2019-05-08

Applicant: DSM IP ASSETS B.V.

Inventor： Daniel GRENFELL-LEE ,  Christian SCHÄFER ,  James TREGANOWAN ,  Carlos SANTOS

IPC: A23L33/10 ,  A23L29/281 ,  A23L33/15 ,  A23K20/179 ,  A23K20/174 ,  A23L29/20 ,  A23L33/14 ,  A23L33/135 ,  A23L5/44 ,  A23L29/00

Abstract: The present invention relates to a solid formulation comprising a carotenoid producing source bioorganism, which is storage stable, as well as the process of production of this formulation.

公开(公告)号：US20160302462A1

公开(公告)日：2016-10-20

申请号：US15101692

申请日：2014-12-05

Applicant: DSM IP ASSETS B.V.

Inventor： Daniel GREENFELL-LEE ,  Christian SCHÄFER ,  James TREGANOWAN ,  Carlos SANTOS

IPC: C12N1/20 ,  A23K20/179 ,  A23K20/174

CPC classification number: A23L33/10 ,  A23K20/174 ,  A23K20/179 ,  A23L5/44 ,  A23L29/065 ,  A23L29/20 ,  A23L29/284 ,  A23L33/135 ,  A23L33/14 ,  A23L33/15 ,  A23V2002/00 ,  A23V2200/324 ,  A23V2250/5114 ,  A23V2250/5432

Abstract: The present invention relates to a solid formulation comprising a carotenoid producing source bioorganism, which is storage stable, as well as the process of production of this formulation.

Abstract translation: 本发明涉及包含类胡萝卜素生产源生物有机体的固体制剂，其储存稳定，以及该制剂的生产过程。

公开(公告)号：US20170157054A1

公开(公告)日：2017-06-08

申请号：US15440630

申请日：2017-02-23

Applicant: DSM IP ASSETS B.V.

Inventor： Markus BECK ,  Hansjoerg GRASS ,  Bruno LEUENBERGER ,  Markus NOWOTNY ,  Christian SCHÄFER ,  Karl Manfred VOELKER

IPC: A61K9/20 ,  A61K31/01 ,  A23L33/155 ,  A23K20/179 ,  A23L5/44 ,  A61K31/047 ,  A23K20/174

CPC classification number: A61K9/2081 ,  A23K20/174 ,  A23K20/179 ,  A23L5/44 ,  A23L33/155 ,  A23V2002/00 ,  A61K8/0241 ,  A61K8/31 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/01 ,  A61K31/047 ,  A61K2800/52 ,  A61K2800/56 ,  A61Q19/00

Abstract: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ≧380, preferably of ≧600, most preferably ≧900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ≦30% when pressed to tablets.